Endometriosis 99mTc Noninvasive Diagnosis — Lancet 2026. 7~10 Year Diagnosis Delay Policy Gap Resolved
Endometriosis affects 1 in 10 women but diagnosis averages 7~10 year delay. Standard = laparoscopy (general anesthesia·invasive). Oxford Nuffield × Serac Healthcare 2026 Lancet — 99mTc-maraciclatide noninvasive molecular imaging endometriosis diagnosis·monitoring. 7~10 year diagnosis delay policy gap first resolution.
Key Announcement
99mTc-maraciclatide Phase 2 (2026): Oxford Nuffield + Serac Healthcare, Lancet Obstetrics Gynaecology Women’s Health 2026, noninvasive molecular imaging diagnostic, Phase 2 positive data, monitoring possible
US trials: 7 Phase 2/3, 2026.6~2029.7 completion, L64 ENDO-205 (non-hormonal drug) linked
Endometriosis - Global Blind Spot
Prevalence: 1 in 10 women (190M+ global), Korea 2.55M estimated, reproductive age (15~45), fertility impact
Symptoms: Chronic pelvic pain, dysmenorrhea (severe period pain), dyspareunia, dyschezia·dysuria, infertility (30~50%), chronic fatigue
7~10 Year Diagnosis Delay: Average 7~10 year delay, ↓ clinician awareness, patient complaint-dependent, “psychological·physiological” misjudgment, standard = laparoscopy (invasive)
99mTc-maraciclatide Mechanism
99mTc: Medical radioactive tracer, gamma camera imaging, 6-hour half-life (safe), various molecular imaging
Maraciclatide: Endometriosis lesion-specific binding, integrin target, active site visualization
Action: IV injection → endometriosis lesion binding, SPECT imaging → lesion location·size visualization, noninvasive (no anesthesia), outpatient
Existing vs 99mTc-maraciclatide
Laparoscopy: General anesthesia, invasive surgery, 1~2 week recovery, ↑ cost, complications risk, only selected patients
99mTc-maraciclatide (L74): Noninvasive (injection + imaging), outpatient, no recovery, ↓ cost (expected), safe, monitoring possible
L74 Dimension - 5th Axis
40 pillars + endometriosis + diagnosis: L64 ENDO-205 non-hormonal endometriosis (drug) + L74 99mTc-maraciclatide (diagnosis) = endometriosis drug + diagnosis integration. 7~10 year diagnosis delay policy gap resolution.
Monitoring Possible
Endometriosis monitoring: Existing symptoms + laparoscopy retest, L74 99mTc imaging tracking, treatment response evaluation, recurrence early detection
Drug trials (L64 ENDO-205): Non-hormonal endometriosis drug, efficacy = 99mTc-maraciclatide imaging changes, drug + diagnosis simultaneous precision
Clinical Burden
Fertility: Infertility 30~50%, IVF outcomes impact, pregnancy complications ↑
Quality of life: Chronic pain, work·daily impact, ↑ depression·anxiety, ↓ sexual function
Economic burden: ↑ medical cost, absence·productivity ↓, Korea estimated annual 1T+ KRW
Global Policy
WHO 2023: Endometriosis priority, diagnosis·treatment gap resolution, education·awareness ↑
National: UK·Australia national guidelines, US ACOG·ASRM guidelines, Korea (development needed)
L74 99mTc significance: Global diagnosis equity policy starting point, noninvasive → ↑ access, average 7~10 year diagnosis → potential shortening
Korean Implications
Korean endometriosis: Diagnosis avg 7~10 year same, laparoscopy standard, hormonal treatment (contraceptive·GnRH agonist), surgery (excision·hysterectomy), integrated care lacking
99mTc-maraciclatide adoption: Post US Phase 2/3 results, Korean MFDS 23 yr, 20292031 expected, $500~$2,000 expected
Daily Guide
Symptom suspicion: OB-GYN immediate visit, period pain intensity·chronic pelvic, family history, dyspareunia·dyschezia
Diagnosis (current): Ultrasound (cyst), MRI (deep endometriosis), laparoscopy (confirmatory), future: 99mTc-maraciclatide noninvasive
Treatment stages: NSAID painkillers, hormones (contraceptive·GnRH agonist·dienogest), surgery, future: L64 ENDO-205 non-hormonal
Fertility planning: Post-diagnosis quick pregnancy plan, IVF eval, OB-GYN + fertility clinic
FAQ
Q. 99mTc-maraciclatide really replaces laparoscopy? A. Phase 2 positive. Phase 3 verification. Some patients (laparoscopy difficult) priority. Full replacement post-verification.
Q. Korea availability?
A. Post US Phase 2/3 Korean MFDS 23 yr. 20292031 expected.
Q. 7~10 year delay reducible? A. Noninvasive diagnosis → ↑ doctor·patient access. But clinician awareness·education·policy together needed.
Q. Endometriosis = hormonal only? A. Hormone + immune + environment multi-axis. L64 ENDO-205 = non-hormonal drug. Multi-axis treatment.
Q. Pregnancy possible? A. Endometriosis + pregnancy 30~50% difficult. But IVF·in vitro·drug help. Post-diagnosis quick fertility planning.
Conclusion
Endometriosis 99mTc-maraciclatide = 7~10 year diagnosis delay policy gap first resolution. Oxford × Serac Phase 2 + US 7 Phase 2/3 progressing. L74 = 55 pillars + expansion·global·policy dimension (endometriosis diagnosis 5th axis). Korea 2029~2031. L64 ENDO-205 drug + L74 99mTc diagnosis = endometriosis precision integrated care.